Establishment and characterization of NCC-MLPS4-C1: a novel patient-derived cell line of myxoid liposarcoma.

Abstract

Myxoid liposarcoma (MLPS) is a malignant tumor composed of uniform, round-to-ovoid cells and small lipoblasts embedded in a myxoid stroma containing branching capillaries. MLPS is characterized by the presence of fusion genes, primarily FUS::DDIT3, with EWSR1::DDIT3 identified in a subset of cases. Although multimodal therapies have improved outcomes for localized MLPS, the prognosis for recurrent or metastatic MLPS cases remains poor, underscoring the need for novel therapeutic strategies. Patient-derived cell lines are essential tools in cancer research, providing various opportunities for discovery to the researchers. However, publicly available MLPS cell lines are lacking, which hinders research on this disease. With this notion, we established an MLPS cell line, NCC-MLPS4-C1. NCC-MLPS4-C1 was derived from the surgically resected tumor of a 48-year-old male patient with MLPS. We performed molecular and phenotypic characterization and high-throughput drug screening to evaluate its potential as a preclinical model. Genetic analysis confirmed the presence of the FUS::DDIT3 fusion gene in the original tumor and NCC-MLPS4-C1. NCC-MLPS4-C1 demonstrated stable proliferation, in vitro spheroid-forming ability, and invasive characteristics. We demonstrated that NCC-MLPS4-C1 is applicable for the global experiments such as drug screening. In conclusion, we successfully established NCC-MLPS4-C1, a novel cell line derived from surgically resected tumor tissue. NCC-MLPS4-C1 will be useful for the cancer research, especially in which the cell lines are required for global experiments.